Pylera for the eradication of Helicobacter pylori infection.

Hdl Handle:
http://hdl.handle.net/10147/207862
Title:
Pylera for the eradication of Helicobacter pylori infection.
Authors:
Saleem, Aamir; Qasim, Asghar; O'Connor, Humphrey J; O'Morain, Colm A
Affiliation:
Adelaide and Meath Hospital, Incorporating the National Children's Hospital,, Tallaght, Trinity College Dublin, Ireland. draamirsaleem@yahoo.co.uk
Citation:
Expert Rev Anti Infect Ther. 2009 Sep;7(7):793-9.
Journal:
Expert review of anti-infective therapy
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207862
DOI:
10.1586/eri.09.55
PubMed ID:
19735221
Abstract:
An ideal antibiotic regimen for Helicobacter pylori should achieve eradication rates of approximately 90%. Current 7-day triple therapy is successful in about two-thirds of patients. A novel treatment is required to achieve higher eradication with minimal induction of bacterial resistance. The aim of this article is to evaluate the safety and efficacy of a single triple capsule (Pylera) containing bismuth, metronidazole and tetracycline, given with omeprazole for the eradication of H. pylori infection. Extensive literature searches were conducted using PubMed data from 1982 to 2007. This search included headings of H. pylori, bismuth and eradication therapy. The triple capsule Pylera, when given with omeprazole, achieved eradication rates ranging between 84 and 97%. Eradication rates were similar for clarithromycin- and metronidazole-resistant strains. Eradication rates with an omeprazole, bismuth, metronidazole and tetracycline regimen appeared comparable for metronidazole-resistant and -sensitive strains. This effect is not seen with the use of triple therapy in cases of clarithromycin resistance. Clinical trials did not report any serious side effects from bismuth-based regimens and compliance was similar to standard triple therapy. Bismuth-based triple therapy using Pylera is a simplified, effective and well-tolerated regimen achieving cure rates of above 90%.
Language:
eng
MeSH:
Administration, Oral; *Antacids/administration & dosage/adverse effects/therapeutic use; *Anti-Bacterial Agents/administration & dosage/adverse effects; Anti-Ulcer Agents/administration & dosage/adverse effects/therapeutic use; *Bismuth/administration & dosage/adverse effects/therapeutic use; *Capsules/administration & dosage/adverse effects/therapeutic use; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections/*drug therapy/microbiology; Helicobacter pylori/*drug effects; Humans; *Metronidazole/administration & dosage/adverse effects/therapeutic use; Omeprazole/administration & dosage/adverse effects/therapeutic use; Randomized Controlled Trials as Topic; *Tetracycline/administration & dosage/adverse effects/therapeutic use; Treatment Outcome
ISSN:
1744-8336 (Electronic); 1478-7210 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorSaleem, Aamiren_GB
dc.contributor.authorQasim, Asgharen_GB
dc.contributor.authorO'Connor, Humphrey Jen_GB
dc.contributor.authorO'Morain, Colm Aen_GB
dc.date.accessioned2012-02-01T10:48:23Z-
dc.date.available2012-02-01T10:48:23Z-
dc.date.issued2012-02-01T10:48:23Z-
dc.identifier.citationExpert Rev Anti Infect Ther. 2009 Sep;7(7):793-9.en_GB
dc.identifier.issn1744-8336 (Electronic)en_GB
dc.identifier.issn1478-7210 (Linking)en_GB
dc.identifier.pmid19735221en_GB
dc.identifier.doi10.1586/eri.09.55en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207862-
dc.description.abstractAn ideal antibiotic regimen for Helicobacter pylori should achieve eradication rates of approximately 90%. Current 7-day triple therapy is successful in about two-thirds of patients. A novel treatment is required to achieve higher eradication with minimal induction of bacterial resistance. The aim of this article is to evaluate the safety and efficacy of a single triple capsule (Pylera) containing bismuth, metronidazole and tetracycline, given with omeprazole for the eradication of H. pylori infection. Extensive literature searches were conducted using PubMed data from 1982 to 2007. This search included headings of H. pylori, bismuth and eradication therapy. The triple capsule Pylera, when given with omeprazole, achieved eradication rates ranging between 84 and 97%. Eradication rates were similar for clarithromycin- and metronidazole-resistant strains. Eradication rates with an omeprazole, bismuth, metronidazole and tetracycline regimen appeared comparable for metronidazole-resistant and -sensitive strains. This effect is not seen with the use of triple therapy in cases of clarithromycin resistance. Clinical trials did not report any serious side effects from bismuth-based regimens and compliance was similar to standard triple therapy. Bismuth-based triple therapy using Pylera is a simplified, effective and well-tolerated regimen achieving cure rates of above 90%.en_GB
dc.language.isoengen_GB
dc.subject.meshAdministration, Oralen_GB
dc.subject.mesh*Antacids/administration & dosage/adverse effects/therapeutic useen_GB
dc.subject.mesh*Anti-Bacterial Agents/administration & dosage/adverse effectsen_GB
dc.subject.meshAnti-Ulcer Agents/administration & dosage/adverse effects/therapeutic useen_GB
dc.subject.mesh*Bismuth/administration & dosage/adverse effects/therapeutic useen_GB
dc.subject.mesh*Capsules/administration & dosage/adverse effects/therapeutic useen_GB
dc.subject.meshDrug Administration Scheduleen_GB
dc.subject.meshDrug Therapy, Combinationen_GB
dc.subject.meshHelicobacter Infections/*drug therapy/microbiologyen_GB
dc.subject.meshHelicobacter pylori/*drug effectsen_GB
dc.subject.meshHumansen_GB
dc.subject.mesh*Metronidazole/administration & dosage/adverse effects/therapeutic useen_GB
dc.subject.meshOmeprazole/administration & dosage/adverse effects/therapeutic useen_GB
dc.subject.meshRandomized Controlled Trials as Topicen_GB
dc.subject.mesh*Tetracycline/administration & dosage/adverse effects/therapeutic useen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.titlePylera for the eradication of Helicobacter pylori infection.en_GB
dc.contributor.departmentAdelaide and Meath Hospital, Incorporating the National Children's Hospital,, Tallaght, Trinity College Dublin, Ireland. draamirsaleem@yahoo.co.uken_GB
dc.identifier.journalExpert review of anti-infective therapyen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.